Journal club of the week: “Paclitaxel nano delivery systems”

Speaker: Ms. Adile Ayati the PhDs
Date: 2nd of May, 2016
Topic: "Paclitaxel nano delivery systems"

In the Recent journal meeting on 2nd of May, 2016, Ms. Adile Ayati the PhDs introduces the participants to “Paclitaxel nano delivery systems”. She talked about the Breast cancer, which is of major concern in this new scenario. Paclitaxel is one of the most effective chemotherapeutic drugs ever developed and is active against a broad range of cancers, such as lung, ovarian, and breast cancers. Due to its low water solubility, paclitaxel is formulated in a mixture of Cremophor EL and dehydrated ethanol (50:50, v/v) a combination known as Taxol. However, Taxol has some severe side effects related to Cremophor EL and ethanol. Therefore, there is an urgent need for the development of alternative Taxol formulations. The encapsulation of paclitaxel in biodegradable and non-toxic nano-delivery systems can protect the drug from degradation during circulation and in-turn protect the body from toxic side effects of the drug thereby lowering its toxicity, increasing its circulation half-life, exhibiting improved pharmacokinetic profiles, and demonstrating better patient compliance. Also, nanoparticle-based delivery systems can take advantage of the enhanced permeability and retention (EPR) effect for passive tumor targeting, therefore, they are promising carriers to improve the therapeutic index and decrease the side effects of paclitaxel. To date, paclitaxel albumin-bound nanoparticles (Abraxane®) have been approved by the FDA for the treatment of metastatic breast cancer and non-small cell lung cancer (NSCLC). In addition, there are a number of novel paclitaxel nanoparticle formulations in clinical trials. She briefly described about the advantages of nano-particles based Paclitaxel delivery system such as polymeric nanoparticles, lipid-based formulations, polymer conjugates, inorganic nanoparticles, carbon nanotubes, nanocrystals, and cyclodextrin nanoparticles. At the conclusion, she said that PX is one of the most effective anticancer drugs ever developed. It is active against a broad range of cancers. However, the current Taxol formulations have issues related to the use of Cremophor EL and ethanol. Since nano-delivery systems could have the potential to be free of Cremophor EL and ethanol, enhance PX solubility, improve PX pharmacokinetic profiles in vivo, decrease its side effects, passively or actively target to tumor sites due to the EPR effect and the use of targeting ligands, respectively, nanotechnology is a very active research area in both academic and industrial settings. Last but not the least, Prof. Dr. Abdollahi put light on the whole presentation and give suggestions, comments about plagiarism in research in this new era. At the end all participants asked their valuable questions and she answered all the questions.